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MDM2 and MDM4 are proteins involved in regulating the tumour suppressor p53. MDM2/4 and p53
interact through their N-terminal domains and disrupting this interaction is a potential anticancer
strategy. The MDM2–p53 interaction is structurally and biophysically well characterised, whereas
equivalent studies on MDM4 are hampered by aggregation of the protein. Here we present the
NMR characterization of MDM4 (14-111) both free and in complexes with peptide and small-mole-
cule ligands. MDM4 is more dynamic in its apo state than is MDM2, with parts of the protein being
unstructured. These regions become structured upon binding of a ligand. MDM4 appears to bind its
ligand through conformational selection and/or an induced ﬁt mechanism; this might inﬂuence
rational design of MDM4 inhibitors.
Structured summary:
MINT-7896835: p53 (uniprotkb:P04637) and MDM4 (uniprotkb:O15151) bind (MI:0407) by isothermal
titration calorimetry (MI:0065)
MINT-7896820: p53 (uniprotkb:P04637) and MDM4 (uniprotkb:O15151) bind (MI:0407) by nuclear mag-
netic resonance (MI:0077)
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction [5]. X-ray crystallographic structures show nutlin bound to theThe tumour suppressor p53 plays a central role in cellular
response to stress signals [1]. Loss of p53 function through
mutation or inactivation is often found in cancer. One inactiva-
tion route involves MDM2, which acts as a speciﬁc E3 ubiquitin
ligase promoting degradation of p53 [2]. MDM2 and p53 interact
primarily through their N-terminal domains; in particular the
100 aa MDM2 N-terminal domain binds to the p53 transactiva-
tion sequence. Upon binding this otherwise unstructured
sequence within p53 adopts a helical fold [3]. Disruption of this
interaction is a strategy to combat some types of cancer [4].
Rational design based on the three-dimensional arrangement of
side chains in the MDM2-bound p53 peptide led to speciﬁc
small-molecule inhibitors, which are exempliﬁed by the nutlinschemical Societies. Published by E
ein; NMR, nuclear magnetic
rankfurter Str. 250, D-64293
.p53 binding cleft of MDM2 [5]. NMR relaxation measurements
[6] suggest that ligand binding does not alter the ﬂexibility
around the cleft, yet they indicate release, upon p53-derived
peptide-binding, of the extreme N-terminal MDM2 ‘‘lid”
from the binding cleft, where it is weakly bound in the apo state
[7,8].
A related protein, MDM4/MDMX [9], resembles MDM2 but
lacks the E3 ligase activity. The two proteins form a heterodimer
that has a higher E3 ligase activity than MDM2 alone [10]. Ele-
vated MDM4 levels have been reported for a variety of tumours
[10,11]. Small molecules with dual MDM2/MDM4 speciﬁcity are
therefore expected to be superior to selective MDM2 binders
such as the nutlins, which bind 40 times more strongly to
MDM2 than to MDM4 [10]. Biophysical properties of MDM4
are not understood at the same level of detail as they are for
MDM2, yet they might explain differences between the proteins
and aid development of ligands with dual-speciﬁcity. Although
several X-ray crystallographic structures are available [12–15],
most studies have been hampered by poor expression and solu-
bility of MDM4. Here we describe the expression and NMR char-
acterization of the MDM4 N-terminal domain in its apo and two
ligand-bound states.lsevier B.V. All rights reserved.
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2.1. Molecular biology
A pET28b (Invitrogen) vector expressing His6 – thrombin cleav-
age site – MDM4 (14-111) (C17S) was synthesized (Geneart,
Regensburg, Germany). The plasmid was transformed into E. coli
BL21 DE3 (Invitrogen) and protein was produced in M9 minimal
media supplemented with 0.5% w/v 15N/13C Celtone (Cambridge
Isotope Laboratories Inc.). Expression was induced at OD600 = 0.6
with 1 mM isopropyl 1-thio-b-D-galactopyranoside (IPTG) at
18 C overnight. Cells were harvested by centrifugation. The frozen
pellet was re-suspended in buffer A (40 mMHEPES pH 7.5, 300 mM
NaCl, 1 mM TCEP, 10% v/v glycerol, 10 mM imidazole) with 1 mg/
ml lysozyme and 2.5 units/ml benzonase. The suspension was
passed twice through a Basic Z 2 Plus (Constant Disruption Sys-
tems Ltd.). The lysates were clariﬁed by centrifugation and the sol-
uble fraction loaded onto a Ni-NTA column (Qiagen). The protein
was eluted with 500 mM imidazole and dialyzed against buffer A
in the presence of thrombin (GE Healthcare) followed by a re-pass
on the Ni-NTA column. Finally, the samples were loaded onto a gel
ﬁltration column (HiLoad 26/60 Superdex 75 GE Healthcare) in 50
mM HEPES pH 7.5, 100 mM NaCl, 2 mM TCEP, 10% v/v glycerol,
0.1 mM EDTA, 0.02% NaN3.
2.2. Peptide synthesis
The p53-derived peptide 17ETFSDLWKLLP27 was synthesized by
solid-phase peptide synthesis using F-moc protection of NH2
groups. Purity was checked by HPLC and MALDI.
2.3. Thermoﬂuor stability assay
A Thermoﬂuor ﬂuorescence-based stability assay was used to
screen for optimal NMR buffer conditions. For this, a mixture of
0.2 mg/ml protein in the buffer of choice (Table 1), and a 1:1000
dilution of Sypro orange dye (Invitrogen) were added in 25 lL ali-
quots into a 96-well PCR plate (Bio-Rad). The plate was heated
using an iCycler iQ instrument (Bio-Rad), with a scan rate of 1 C/
min from 20 to 90 C. Data were collected at 0.2 C increments,
and analysed using GraphPad Prism 4 software.
2.4. Dynamic light scattering
Dynamic laser light scattering measurements were performed
using a Wyatt DynaPro Titan plate-reader instrument. Apo-
MDM4 (14-111) protein samples (50 lL) were prepared at both
50 and 100 lM in a range of buffers. Samples were ﬁltered, centri-
fuged and aliquoted into Thermo (Cat. 95040000) 384 well plates.
Measurements were made using a laser power of 10%, for ten
acquisitions, each of 10 s duration. Data were analysed using the
DYNAMICS V6 software.
2.5. NMR spectroscopy
NMR spectra were recorded on Bruker Avance 600 and Avance2
800 spectrometers at 600 and 800 MHz proton resonance fre-Table 1
Buffer conditions screened for NMR by thermoﬂuor assay. Two salts were screened,
(NH4)2SO4 and NaCl at different concentrations for each pH point.
Buffer system pH range Salt concentration
MES 4.4–6.4 10 mM, 155 mM
Citrate 5.8–7.8 10 mM, 155 mM
Phosphate 5.8–7.8 10 mM, 155 mM
MOPS 6.2–8.2 10 mM, 155 mMquency. Typical NMR samples contained 0.1 mM single-labeled or
double-labeled MDM4 (14-111) in 100 mM NaCl, 50 mM BisTris
pH 6.5, 2 mm TCEP, 0.1 mM EDTA, 0.1% NaN3 and 1% DMSO-d6 as
a lock solvent.
Ligands were added as concentrated solutions in DMSO-d6 and
any resulting precipitate was removed by centrifugation. Nutlin-3
(Sigma–Aldrich) was used as a racemic mixture. The nutlin-
3:MDM4 (14-111) complex was prepared at low concentrations
initially prior to concentration and addition of excess nutlin-3.
Assignment followed a standard route using TROSY-type HNCA,
HNCACB, HN(CO)CACB, HNCO and HN(CA)CO experiments at
800 MHz. Side-chains were partially assigned using HSQC-type
H(CC)(CO)NH-TOCSY and CC(CO)NH-TOCSY experiments at 600
MHz. Triple resonance data were evaluated using CARA 1.5.5 [16].
2.6. Isothermal titration calorimetry
The interaction of MDM4 (14-111) with p53 (17ETFSDLWKLLP27)
and nutlin-3was quantiﬁed using aMicrocal ITC 200 (GE Healthcare)
ﬁtted with an autosampler. The titration data were recorded at 25 C
in 50 mM HEPES pH 7.5, 100mMNaCl, 2 mM TCEP, 10% v/v glycerol,
0.02% NaN3, 2% DMSO. Aliquots of 200 lM ligand stocks in buffer
were added to 20 lM MDM4 (14-111) in multiple 0.8 ll steps. Data
were analysed using Origin (Microcal).
3. Results and discussion
3.1. Optimization of construct and expression conditions
Two constructs were used for initial expression trials. Native
MDM4(1-134) was produced in high quantities but turned out to
be very unstable and only poorly soluble. We therefore utilized a
construct originally designed for crystallographic work, the
MDM4 (14-111) (C17S) mutant [13]. This construct was subse-
quently used for all NMR and biophysical studies.
Since initial trials suggested low yields of recombinant MDM4
(14-111), we undertook a systematic small-scale screen for opti-
mal expression conditions. This utilized three strains of E. coli
BL21 (DE3, Star and GOLD), two media (TB and M9), three temper-
atures (37, 25 and 18 C) and three IPTG induction concentrations
(0.05, 0.1 and 1 mM). All possible combinations of these parame-
ters were screened and compared for their yield of soluble
MDM4 (14-111). Our results indicate better yields at lower tem-
perature and high IPTG concentrations. They furthermore indicate
poor yield in minimal M9 medium, and the need for supplementa-
tion of the media with Celtone for acceptable expression yield.
Relatively poor yield and stability of the MDM4 N-terminal do-
main reported in previous studies highlighted the necessity for
construct improvements. Although our construct had been de-
signed for crystallography, it proved to be equally suitable for col-
lecting NMR data. We did not, however, undertake a systematic
study to ﬁnd the optimal construct for an NMR-based study. For
example, MDMX-S [17], a native, shortened construct, might have
superior properties in this respect.
3.2. Optimisation of NMR conditions
Preliminary experiments indicated aggregation of MDM4 (14-
111) under typical conditions used for NMR data collection (neu-
tral pH, 300–310 K and low ionic strength). Self-association might
be exacerbated by transient exposure of hydrophobic residues that
are predominantly buried within compactly folded apoMDM4 (14-
111) molecules. We reasoned that in order to minimise aggrega-
tion we should attempt to optimise conditions with respect to
the thermal stability of these folded form(s) of the protein. We
therefore conducted a Thermoﬂuor-based screen [18] that allows
Fig. 1. (a) Annotated TROSY spectrum of MDM4 (14-111) in complex with a p53-derived peptide. (b) TROSY spectra for apo MDM4 (black), MDM4–p53 complex (blue) and
MDM4–nutlin-3 (red). (c) Extent of assignment for apo MDM4 (top), the p53–MDM4 complex (middle) and the MDM4–nutlin-3 complex (bottom).
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zation studies [19] (Table 1). Thermoﬂuor data suggested that
MDM4 (14-111) is most stable at high salt concentrations and
pH above 6 (Supplementary data), and that ammonium sulfate is
preferable to sodium chloride with respect to the thermal stability
of recombinant MDM4 (14-111). Dynamic light scattering studieswere used to more directly monitor the salt and pH-dependencies
of MDM4 (14-111) self-association. These studies, however, indi-
cated a higher degree of protein aggregation at 20 C in ammonium
sulfate buffer compared to equivalent sodium chloride buffer con-
ditions (Supplementary data). All subsequent NMR experiments
were therefore carried out in 100 mM NaCl; pH 6.5 was used, as
Fig. 2. Chemical shift perturbations induced by binding of p53 peptide to MDM4 (14-111). (a) Chemical shift perturbations for amide (lower panel) and carbon (upper panel)
nuclei. Asterisks denote amide signals not detectable for apo MDM4. (b) Mapping of chemical shift perturbations on the three-dimensional structure (pdb code 3FE7 [13]) of
MDM4 N-terminal domain. Unassigned residues in the apo protein are marked in white while chemical shift perturbations are mapped in red. Chemical shift perturbations
are geometric sums of all available chemical shift differences (Ca, Cb, CO, N and H) weighed by relative gyromagnetic ratios of nuclei.
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indicated slightly better sensitivity for TROSY-based than for
HSQC-based experiments. This was ascribed to residual aggrega-
tion and prompted us to limit concentrations to 100 lM. The con-
sequent low protein concentration and high salt content
necessitated recording of all assignment experiments with a cryo-
probe and using a salt-tolerant sample tube.3.3. NMR assignment
Only 66 out of 93 expected amide cross peaks were detected in
the resulting 1H/15N correlation spectra, despite efforts to optimise
conditions. Consequently it was impossible to fully assign nuclei of
the apo state using a conventional assignment strategy. Addition of
the p53-derived peptide to the labeled MDM4 (14-111) sample led
Fig. 3. Chemical shift perturbations induced by binding of nutlin-3 to MDM4. Cf. ﬁgure caption for Fig. 2 for details.
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binding of peptide to protein. Additional peaks became detectable
in NMR spectra of this complex, yielding all 93 expected cross
peaks. We observed similar effects upon formation of the MDM4
(14-111)–nutlin-3 complex, although fewer peaks emerged (yield-
ing a total of 80 cross peaks) and chemical shift perturbations were
generally smaller. A set of NMR spectra collected on the complex
with peptide, which showed by far the best signal-to-noise in the3D correlation experiments, enabled a complete assignment of
the MDM4 (14-111) backbone Ca, Cb, NH, HN and CO resonances
in the MDM4–p53 peptide complex (Fig. 1a).
The assignments obtained for the MDM4 (14-111)–peptide
complex were used to assist assignment of the apo and nutlin-3
bound forms of MDM4 (14-111). Direct assignment transference
in the 2D TROSY spectrum proved to be difﬁcult due to large chem-
ical shift differences and missing peaks, as discussed above. There-
3040 M.C. Sanchez et al. / FEBS Letters 584 (2010) 3035–3041fore, the 13C chemical shift information in 3D triple resonance
experiments was used to infer assignments of the majority of
peaks in the 2D TROSY spectrum. We simultaneously obtained a
chemical shift perturbation map of Ca, NH, HN, CO and Cb chemical
shifts, as well as identifying the missing peaks. Chemical shifts
have been uploaded to the BMRB data base with accession codes
16893 (apo MDM4), 16900 (MDM4–p53 complex) and 16894
(MDM4–nutlin-3 complex).
3.4. Chemical shift mapping of ligands on MDM4
Lack of amide signals is often caused by conformational transi-
tions on the millisecond time scale and concomitant line broaden-
ing in the intermediate-exchange regime. Indeed very broad
residual peaks were found in TROSY spectra of the apo MDM4
(14-111) at positions corresponding to several cross peaks that
emerged upon complexation of MDM4 (14-111) with peptide. This
suggests MDM4 (14-111) is a ﬂexible protein in the apo state that
is rigidiﬁed by binding to a fragment of its natural ligand. Nutlin-3
appears to be less well able to rigidify MDM4 (14-111) based on
the presence of only 13 new cross peaks in TROSY spectra of its
complex with MDM4 (14-111).
One obvious difference between MDM2 and MDM4 that simpli-
ﬁes interpretation of chemical shift perturbation is the lack of a lid
in MDM4 [20]. Therefore in MDM4 no effects on chemical shifts
due to release of the N-terminus, which have been described for
the equivalent MDM2 complex [6], need be invoked upon binding
of peptide. Mapping onto its 3D structure the chemical shift pertur-
bations inducedbybindingof peptide ornutlin-3 toMDM4(14-111)
highlights speciﬁc regions on the protein surface (Figs. 2 and 3).
Notably, perturbations of amide chemical shifts probe different
phenomena than changes in carbon chemical shifts (for Ca and CO).
Perturbations of amide resonances arise principally from direct
interactions between the ligand and the protein [21] and therefore
can be used to infer the location of the binding site. As expected the
strongest effects on amide peaks correspond to residues lining the
hydrophobic cleft. Perturbations of carbon shifts, on the other
hand, arise primarily from modulations in secondary structure
and therefore indicate changes in structure and backbone dynam-
ics [22]. We observed large carbon chemical shift differences for
residues in helices a2 and a20 that form the peptide-binding cleft.
Furthermore, signals for the N-terminal end of helix a10 and an
adjacent loop, which are located at the opposite wall of the hydro-
phobic cleft, are detectable only in ligand-bound MDM4 (14-111).
These observations suggest that this region is less structured in the
apo protein than it is in either of the complexes. In summary, both
the sharper (i.e. more easily detected) cross peaks in the spectra of
the complex, and the locations within the protein of residues expe-
riencing carbon chemical shift perturbations upon ligand binding,
suggest MDM4 (14-111) is relatively ﬂexible in its free state but
less so when complexed with ligands. P53 binds via either one or
a combination of the following: an induced ﬁt mechanism or selec-
tion and stabilization of one out of multiple conformations. We
have insufﬁcient data to distinguish between these mechanisms.
Flexibility of apo-MDM4 N-termini might also explain the poor
yield and aggregation tendency of MDM4 observed by us and other
groups. In general the effects on the NMR spectra resulting from
complexation of MDM4 (14-111) with nutlin-3 are less signiﬁcant
than those observed for p53 (Fig. 3). This suggests that nutlin-3 is
not capable of inducing an equivalent degree of conformational
adjustment and rigidiﬁcation. This is not unexpected for a smaller,
less ﬂexible molecule that lacks the adaptability of the larger
peptide. Furthermore,previous structural studies [12] indicated that
steric hindrance between nutlin-3 and amino acid side chains (of
M53 and Y99) would be likely to prevent nutlin-3 from binding to
MDM4 (14-111) in the same mode as it does to MDM2 [15].MDM2, by contrast, appears to be more structured than MDM4
in its apo form. This conclusion is based on the number of cross
peaks observable in spectra of the former and the extent of assign-
ment that was possible for apo MDM2 [8]. Excluding release of the
N-terminal lid, ligands have less impact on dynamics [6,8] or car-
bon shifts [6] of MDM2 than they do on MDM4. However, some
widening of the cleft was observed when comparing the structures
of apo and peptide-bound MDM2 [8], with the helices a2 and a20
acting as hinges. It is reasonable to expect similar structural rear-
rangements in MDM4, and local unfolding in the hinges might
facilitate the necessary movements. Isothermal titration calorime-
try studies on MDM2 [14] and MDM4 found large unfavorable
entropic contributions for both proteins, which could be explained
by reduced conformational mobility in both cases. Recent crystal-
lographic studies of small-molecule ligand binding to MDM4 [23]
also suggest an induced ﬁt mechanism and large structural
changes within the a20 helix. For development of dual-speciﬁcity
MDM2/MDM4 binders it will be important to understand subtle
differences in the dynamic behavior of both proteins and relative
contributions of induced ﬁt or conformational selection in each
case. More detailed NMR relaxation studies are therefore needed
to fully understand MDM4 dynamics and how it is inﬂuenced by
ligand binding.
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